Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Nuevo enfoque para el tratamiento de la diabetes mellitus

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TODE20160826001
Publicado:
12/09/2016
Caducidad:
12/09/2017
Resumen:
Una universidad alemana ha desarrollado un nuevo enfoque para el tratamiento de la diabetes mellitus. Los investigadores han identificado una enzima, la proteína quinasa MST-1, responsable de la formación de la enfermedad. La inhibición de esta enzima permite prevenir el desarrollo de la diabetes tipo 1 y 2. Los científicos están llevando a cabo una intensa investigación sobre la implicación de la proteína quinasa MST-1 en procesos apoptópicos de células beta. La universidad busca socios interesados en establecer acuerdos de investigación para continuar con las pruebas o interesados en licenciar o comprar la tecnología.

Details

Tittle:
New approach for the treatment of diabetes mellitus
Summary:
A German University has developed a new approach for the treatment of diabetes mellitus. The researchers have identified a key enzyme, protein kinase MST-1, which is responsible for the formation of the diabetes disease. By inhibiting the enzyme, the development of both type 1 and 2 can be prevented. The university is now looking for partners interested in research cooperation agreements for further testing. Furthermore, partners interested in licensing or purchasing the technology are sought.
Description:
Diabetes mellitus is a metabolic disorder which causes increased blood sugar levels. The disease destroys the insulin-producing cells of the pancreas, the beta cells of the islets of Langerhans. This causes a lack of the blood sugar-reducing hormone insulin, resulting in a chronically increased blood sugar level. More than 400 million people are affected by this disease worldwide.

Researchers of molecular diabetology of a German University have now identified a key enzyme,protein kinase MST-1, which is responsible for the death of these insulin-producing cells due to apoptosis (programmed cell death) and thus for the formation of the diabetes disease. This is valid for both forms of diabetes, namely the autoimmune type 1 and type 2, which depends on age and obesity.

The scientists are carrying out intensive research on the involvement of the protein kinase MST-1 in the apoptopic processes in the beta cells. MST-1 plays a key role in the stimulation of specific signal path cascades. It was possible to demonstrate in experiments that MST-1 inhibition can prevent the formation of both type 1 and type 2 diabetes.

Influencing the protein kinase MST-1 is therefore a promising therapeutic objective for the development of suitable therapies to treat both forms of diabetes.

A series of laboratory tests have been carried out. The targeted inhibition of MST-1 was able to maintain the secretion of insulin and prevent the disease from progressing.

In order to carry out in vivo and in vitro tests that can show which MST 1 inhibitors can prevent diabetes, the University is now looking for partners (pharmaceutical companies) interested in research cooperation agreements. Furthermore, partners interested in licensing or purchasing the technology are sought.
Advantages and Innovations:
- Clarification of the role of MST-1 in the formation of the apoptosis provides a new aim for taking an effective therapeutic approach to diabetes.
- Protection of the beta cells by inhibiting the MST-1 prevents diabetes from progressing or from arising altogether.
-The inhibition of MST-1 results in the prevention of hyperglycemia and in an improved glucose tolerance. It was possible for the first time to demonstrate this in a mouse model.

- The treatment of diabetes and its sequelae (neural injuries, circulatory disorders in the legs and feet, eye and kidney damage) lead to enormous costs for the health care system which could be reduced via early treatment and the possibility of curing the disease.
- According to the Diabetes Atlas of the International Diabetes Federation (IDF), more than 400 Million people (with a rising tendency) affected by diabetes worldwide. There is therefore major
demand for suitable and efficient therapy options.
- Efficient solutions and innovative approaches to curing diabetes are currently the subject of interest of many pharmaceutical companies.
Stage of Development:
Under development/lab tested
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
Patents have been applied for in Europe and the United States

Partner sought

Type and Role of Partner Sought:
- Type of partner sought: Pharmaceutical companies.

- Task to be performed by the partner sought: In vivo and in vitro testing that can show which MST 1 inhibitors can prevent diabetes in the framework of a research cooperation agreement.

Furthermore, the German University is interested in licensing or selling the technology to potential partners in the framework of a license agreement or a commercial agreement with technical assistance.

Client

Type and Size of Client:
R&D Institution
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
German

Keywords

Technology Keywords:
06002007 Ensayos in vitro, experimentos
06001002 Investigaciones clínicas, ensayos
06001012 Investigaciones médicas